It’s back to school for biotech, with a packed conference schedule.

BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.

Darzalex added another string to its bow, while Kisqali’s early use has been delayed.

But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.

Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

The group plays down upcoming interim analysis, but still hopes for accelerated approval.